DE60043830D1 - Durch nicht-kovalent assoziierte Konjugate gebildete Epitope - Google Patents

Durch nicht-kovalent assoziierte Konjugate gebildete Epitope

Info

Publication number
DE60043830D1
DE60043830D1 DE60043830T DE60043830T DE60043830D1 DE 60043830 D1 DE60043830 D1 DE 60043830D1 DE 60043830 T DE60043830 T DE 60043830T DE 60043830 T DE60043830 T DE 60043830T DE 60043830 D1 DE60043830 D1 DE 60043830D1
Authority
DE
Germany
Prior art keywords
conjugates
ligand
covalently associated
epitopes formed
interacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60043830T
Other languages
English (en)
Inventor
Roger New
Istvan Toth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mozaic Discovery Ltd
Original Assignee
Mozaic Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mozaic Discovery Ltd filed Critical Mozaic Discovery Ltd
Application granted granted Critical
Publication of DE60043830D1 publication Critical patent/DE60043830D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432Liposomes or microcapsules
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/525Tumor necrosis factor [TNF]
DE60043830T 1999-06-28 2000-06-27 Durch nicht-kovalent assoziierte Konjugate gebildete Epitope Expired - Fee Related DE60043830D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9915074.0A GB9915074D0 (en) 1999-06-28 1999-06-28 Ligand-binding composition

Publications (1)

Publication Number Publication Date
DE60043830D1 true DE60043830D1 (de) 2010-03-25

Family

ID=10856190

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60036106T Expired - Lifetime DE60036106T2 (de) 1999-06-28 2000-06-27 Durch nicht-kovalent assoziierte konjugate gebildete epitope
DE60043830T Expired - Fee Related DE60043830D1 (de) 1999-06-28 2000-06-27 Durch nicht-kovalent assoziierte Konjugate gebildete Epitope

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60036106T Expired - Lifetime DE60036106T2 (de) 1999-06-28 2000-06-27 Durch nicht-kovalent assoziierte konjugate gebildete epitope

Country Status (18)

Country Link
US (2) US7413538B1 (de)
EP (2) EP1190255B1 (de)
JP (1) JP4754136B2 (de)
KR (1) KR100917285B1 (de)
CN (1) CN100354628C (de)
AT (2) ATE457460T1 (de)
AU (1) AU775310B2 (de)
BR (1) BR0012002A (de)
CA (1) CA2377783C (de)
DE (2) DE60036106T2 (de)
DK (1) DK1190255T3 (de)
ES (1) ES2292446T3 (de)
GB (1) GB9915074D0 (de)
HK (1) HK1045369A1 (de)
IL (2) IL147249A0 (de)
PT (1) PT1190255E (de)
RU (1) RU2259194C2 (de)
WO (1) WO2001001140A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504364B2 (en) * 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
US7469076B2 (en) 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
EP1613737A4 (de) 2003-03-28 2008-12-03 Receptors Llc Reversibel immobilisierte bausteine beinhaltend künstliche rezeptoren und verfahren
EP1789797A1 (de) 2004-09-03 2007-05-30 Receptors LLC Kombinatorische künstliche rezeptoren mit anbindungsbausteinen
EP1789792A2 (de) 2004-09-11 2007-05-30 Receptors LLC Kombinatorische künstliche rezeptoren mit peptidbausteinen
DK2081952T3 (da) 2006-09-20 2014-04-28 Lexcicon Ltd Peptider
KR100840619B1 (ko) * 2006-12-19 2008-06-24 한양대학교 산학협력단 표면개질된 리포좀, 이를 포함하는 바이오칩 및 그제조방법
EP2231180B1 (de) * 2008-01-16 2016-08-17 Ben-gurion University Of The Negev Research And Development Authority Impfstoff für die alzheimerkrankheit
EP2391370B1 (de) 2009-02-02 2015-06-03 Galmed Research and Development Ltd. Verfahren und zusammensetzungen zur behandlung von alzheimer-krankheit
RU2500813C1 (ru) * 2012-10-15 2013-12-10 Федеральное казенное учреждение здравоохранения Ставропольский научно-исследовательский противочумный институт Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ получения липосомально-иммунопероксидазного конъюгата
KR101491728B1 (ko) * 2012-12-14 2015-02-11 주식회사 휴메딕스 비타민 c와 비타민 b3의 컨쥬게이트 및 그를 포함하는 항산화제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3546150A1 (de) * 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
US6074650A (en) 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US6024964A (en) 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
DE3813821A1 (de) * 1988-04-22 1989-11-02 Hoechst Ag Synthetische vakzine gegen die maul- und klauenseuche und verfahren zu deren herstellung
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
EP0548024B1 (de) * 1991-12-19 1997-01-08 Ciba-Geigy Ag Aminosulfonsäurederivate und Verfahren zu ihrer Herstellung
WO1993022343A1 (en) * 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
GB9215780D0 (en) * 1992-07-24 1992-09-09 Univ London Pharmacy Peptide compounds
JP2579730B2 (ja) * 1993-01-22 1997-02-12 株式会社ディ・ディ・エス研究所 ペプチド−脂質誘導体及びリポソーム
HUT73100A (en) * 1993-07-16 1996-06-28 Harvard College Regulated apoptosis
JP3759759B2 (ja) * 1994-03-04 2006-03-29 日本油脂株式会社 リポソームおよび薬物運搬体
DK0706799T3 (da) * 1994-09-16 2002-02-25 Merck Patent Gmbh Immunkonjugater II
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
US5851536A (en) * 1995-11-22 1998-12-22 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
CA2260761C (en) * 1996-06-25 2011-05-03 Nico Johannes Christiaan Maria Beekman Vaccine comprising antigens bound to carriers through labile bonds
JPH10234372A (ja) * 1997-02-27 1998-09-08 Boehringer Mannheim Corp キメラ受容体を有する細胞とその作成方法、並びに その利用
US6217886B1 (en) * 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2776926B1 (fr) * 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
JP2002510706A (ja) * 1998-04-07 2002-04-09 ロシュ ダイアグノスティックス ゲーエムベーハー Dnaトランスフェクションのための新規化合物
WO2000054807A1 (fr) * 1999-03-17 2000-09-21 Mitsubishi Chemical Corporation Complexe lie par un ligand
AU3673500A (en) * 1999-04-08 2000-11-14 Mitsubishi Chemical Corporation Fine particles targeting cells and process for producing the same
JP4111368B2 (ja) * 1999-04-23 2008-07-02 三菱化学株式会社 抗体およびポリアルキレングリコール結合リポソーム
MXPA01010750A (es) * 1999-04-23 2003-08-20 Alza Corp Conjugado que tiene un enlace dividible para utilizarse en un liposoma.

Also Published As

Publication number Publication date
EP1190255B1 (de) 2007-08-22
EP1722227B1 (de) 2010-02-10
RU2259194C2 (ru) 2005-08-27
CN100354628C (zh) 2007-12-12
BR0012002A (pt) 2002-03-12
AU5692300A (en) 2001-01-31
HK1045369A1 (en) 2002-11-22
DK1190255T3 (da) 2007-12-10
GB9915074D0 (en) 1999-08-25
EP1722227A3 (de) 2007-02-28
JP4754136B2 (ja) 2011-08-24
EP1190255A1 (de) 2002-03-27
PT1190255E (pt) 2007-09-18
IL147249A (en) 2007-08-19
DE60036106T2 (de) 2008-05-15
KR20020042537A (ko) 2002-06-05
ATE371190T1 (de) 2007-09-15
EP1722227A2 (de) 2006-11-15
ES2292446T3 (es) 2008-03-16
WO2001001140A1 (en) 2001-01-04
CA2377783A1 (en) 2001-01-04
US7413538B1 (en) 2008-08-19
CN1359469A (zh) 2002-07-17
DE60036106D1 (de) 2007-10-04
IL147249A0 (en) 2002-08-14
ATE457460T1 (de) 2010-02-15
AU775310B2 (en) 2004-07-29
US20080152703A1 (en) 2008-06-26
CA2377783C (en) 2010-03-23
KR100917285B1 (ko) 2009-09-11
JP2003503424A (ja) 2003-01-28

Similar Documents

Publication Publication Date Title
DE60043830D1 (de) Durch nicht-kovalent assoziierte Konjugate gebildete Epitope
DK1674111T3 (da) Anti-glyypican-3-antistof
GB0526205D0 (en) Aircraft seat assembly
DE3883634T2 (de) Dreidimensionales Hochgeschwindigkeits-Solenoid mit zweifachem Luftspalt.
DE266850T1 (de) Latexzusammensetzungen, brauchbar als bindemittel in karton mit raeumlicher stabilitaet und staerke.
ATE397458T1 (de) Neue heilmittel für krebs
MY109894A (en) Belt transfer section and method of use for right angle blank feeder.
DE68900359D1 (de) Dichtungsanordnung, insbesondere fuer einen spielnachsteller fuer schienenfahrzeuge.
HK1063145A1 (en) Holding device for a denture or base structure model
IT8319895A0 (it) Combustione ricca-povera, a bassa combustore perfezionato a produzione di no x.
FR2662380B1 (fr) Manipulateur pour machines de forgeage, par exemple pour machines de forgeage a coulisseaux multiples.
EP1247658A3 (de) Ordner
GB2385519B (en) Folding linkage
AR023979A1 (es) Procesos para preparar compuestos intermedios de plaguicidas
EP0991112A3 (de) Fahrbarer Transportwagen
USD1019877S1 (en) Fly tying vise
ES2035334T3 (es) Maquina para brochar.
NL194043B (nl) 5-Fluoruracilderivaat, alsmede een dergelijk derivaat omvattend farmaceutisch preparaat met kankerbestrijdende werking.
WO2005032247A8 (en) Wobbler with means for varying the length of the wobbler body.
ES1047916U (es) Encuadernacion perfeccionada.
DE502006008803D1 (en) Toaster
ES2101812T3 (es) Maquina circular multi alimentada para tejer punto.
ECSP982594A (es) Oxazolidinonas triciclicamente sustituidas
ES454899A1 (es) Perfeccionamientos en maquinas con transportador de hojas para formar juegos de hojas intercaladas.
ES1013092U (es) Dispositivo para ensamblar dos piezas formando angulo.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee